About Tap pharmacuticals
Tap Pharmaceuticals: Bringing Better Health and a Brighter Future to Patients
Tap Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, is a global research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. With over 230 years of experience in the industry, Tap Pharmaceuticals has established itself as one of the leading pharmaceutical companies in the world.
At Tap Pharmaceuticals, we believe that every patient deserves access to innovative medicines that can improve their quality of life. That's why we focus our R&D efforts on oncology, gastroenterology, central nervous system therapeutic areas plus vaccines. We conduct R&D both internally and with partners to stay at the leading edge of innovation.
Our commitment to oncology is reflected in our portfolio of innovative products that are designed to treat various types of cancer. Our products include Adcetris (brentuximab vedotin), which is approved for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma; Ninlaro (ixazomib), which is approved for multiple myeloma; Alunbrig (brigatinib), which is approved for non-small cell lung cancer; and Iclusig (ponatinib), which is approved for chronic myeloid leukemia.
In addition to oncology, we also have a strong presence in gastroenterology with our flagship product Prevacid (lansoprazole). Prevacid is used for the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcer disease. We also have Entyvio (vedolizumab) in our portfolio, which is used for treating inflammatory bowel disease.
Furthermore, we are committed to developing new treatments for central nervous system disorders such as depression, schizophrenia, bipolar disorder and Alzheimer's disease. Our pipeline includes several promising compounds that are currently in clinical development.
At Tap Pharmaceuticals, we are dedicated to improving the lives of patients around the world. We believe that our success is measured by the impact we have on patients' lives. That's why we strive to develop innovative medicines that can make a real difference in people's lives.
In conclusion, Tap Pharmaceuticals is a global pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. With our focus on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines, we are at the forefront of innovation in the industry. Our commitment to developing new treatments for various diseases reflects our dedication to improving patient outcomes. We will continue to work tirelessly towards achieving our mission of making a positive impact on people's lives through innovative medicines.